#7 - Exscientia (NASDAQ:EXAI)
The development of the first mRNA vaccines for Covid-19 has opened the door to the field of precision medicine. Like Schrodinger, that’s the bullish thesis for Exscienta plc (NASDAQ: EXAI). The UK-based company is “re-imagining the way drug discovery is implemented, combining the latest AI technique with experimental innovation to engineer a new set of processes for drug discovery.”
One of the intriguing elements of the company is that they are focusing on finding oncology drugs. The company has an extensive pipeline but only has one candidate in the early clinical trial phase.
That means it could be years before the company has a commercially available product. And that also means that investors will be waiting for profit and meaningful revenue. That’s plenty of risks. But if you’re looking for long-term investments, EXAI stock has a consensus price target of over $15, which is a gain of 159% from its current price.
About Exscientia
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
Read More - Current Price
- $4.84
- Consensus Rating
- Hold
- Ratings Breakdown
- 0 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $7.00 (44.6% Upside)
Artificial intelligence is going to touch many aspects of our life. You already experience AI in your smartphone and streaming services. In the future, AI will expand into areas such as content creation to elective surgeries and so much more. It's going to be nearly impossible to avoid the impact of AI in our lives.
Still, this is an emerging field. While many AI stocks may be in investor's portfolios for reasons other than the company's exposure to AI, there are other names that are less familiar. That doesn't mean they're bad investments, it just means that you'll have to make sure you do your due diligence.
If you're looking for exposure to AI without the need to pick individual stocks, you can consider one of the many artificial intelligence exchange-traded funds (ETFs). Some of the popular choices include the Global X Robotics & Artificial Intelligence ETF (NASDAQ:BOTZ) and the iShares Robotics and Artificial Intelligence ETF (NYSEARCA:IRBO).
More Investing Slideshows:
